EX-99.3 4 pacb-20140724ex993f53ee6.htm EX-99.3 Q2FY2014 PR 8-K Filed Exhibit 99.3

 

Exhibit 99.3

PACIFIC BIOSCIENCES OF CALIFORNIA, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Six-Month Periods Ended June 30,

(in thousands)

2014

 

2013

Cash flows from operating activities

 

 

 

 

 

Net loss

$

(38,022)

 

$

(41,575)

Adjustments to reconcile net loss to net cash used in operating activities

 

 

 

 

 

Depreciation

 

2,311 

 

 

2,897 

Amortization of debt discount and financing costs

 

375 

 

 

248 

Stock-based compensation

 

4,492 

 

 

5,190 

Other

 

156 

 

 

(73)

Changes in assets and liabilities

 

 

 

 

 

Accounts receivable

 

(1,509)

 

 

(1,282)

Inventory

 

610 

 

 

(293)

Prepaid expenses and other assets

 

 

 

1,229 

Accounts payable

 

3,662 

 

 

(384)

Accrued expenses

 

459 

 

 

699 

Deferred service revenue

 

1,582 

 

 

(97)

Deferred contractual revenue

 

(3,392)

 

 

 —

Other liabilities

 

(607)

 

 

(541)

Net cash used in operating activities

 

(29,876)

 

 

(33,982)

Cash flows from investing activities

 

 

 

 

 

Purchase of property and equipment

 

(942)

 

 

(577)

Purchase of investments

 

(66,876)

 

 

(111,524)

Maturities of investments

 

76,195 

 

 

99,373 

Net cash provided by (used in) investing activities

 

8,377 

 

 

(12,728)

Cash flows from financing activities

 

 

 

 

 

Proceeds from issuance of common stock from equity plans

 

2,691 

 

 

1,283 

Proceeds from issuance of common stock from at-the-market equity offering, net of issuance costs

 

20,646 

 

 

19,954 

Proceeds from issuance of Facility Agreement, net of issuance costs

 

 —

 

 

19,766 

Net cash provided by financing activities

 

23,337 

 

 

41,003 

Net increase (decrease) in cash and cash equivalents

 

1,838 

 

 

(5,707)

Cash and cash equivalents at beginning of period

 

26,362 

 

 

46,540 

Cash and cash equivalents at end of period

$

28,200 

 

$

40,833